Skip to content

Depression: all studies

Page 258 of 1,034: studies 2,571 to 2,580 of 10,336, newest first. Back to the depression overview

Research

Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.

BMC Psychiatry November 29, 2019 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al.

There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown repeatedly in this population, but there is still a paucity of data on the efficacy and safety of (a) different routes of administration, and (b) ketamine's...

A mindfulness and compassion-based program applied to pregnant women and their partners to decrease depression symptoms during pregnancy and postpartum: study protocol for a randomized controlled trial.

Trials November 28, 2019 Olga Sacristan-Martin, Miguel Á Santed, Javier García-campayo et al.

Background: Pregnancy and the postpartum period are times of great change for women and their partners, often bringing substantial challenges and stress. Approximately 10%-20% of women suffer from mood disorders such as depression in the perinatal period. There are risks involved in using psychopharmacological interventions to treat perinatal depression. Mindfulness and compassion-based...

DOI: 10.1186/s13063-019-3739-z (opens in new tab) Full text (opens in new tab) Mindfulness Humans Pregnancy complications Depression, postpartum +6

Psilocybin-assisted therapy for depression: How do we advance the field?

Australian & New Zealand Journal of Psychiatry November 22, 2019 Sally Meikle, Paul Liknaitzky, Susan L. Rossell et al. 19 citations

In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment,...

DOI: 10.1177/0004867419888575 (opens in new tab) Psilocybin Hallucinogen Psychotherapist Depression economics +4

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.

Journal of Affective Disorders November 14, 2019 Fernanda S. Correia-Melo, Gustavo C. Leal, Flávia Vieira et al. 188 citations

BACKGROUND Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression. However, racemic ketamine and esketamine have not been directly compared. The aim of this study is to assess the efficacy and safety of esketamine compared to ketamine in patients with treatment-resistant depression (TRD). METHODS This is a...

Severe Melancholic Depression: Urgent ECT and Utilizing Ketamine (Node 3a)

November 2, 2019

The algorithm for depressed inpatients with melancholia starts with considering whether there is an urgent indication for ECT. Imminent risk of suicide, catatonia, inadequate oral intake, and a past history of good response to ECT may be indications for ECT. Remission rates of 75% have been reported with ECT. If the patient has these indications but refuses or is intolerant of ECT, consider an...

Esketamine for depression: Exciting, but reality is difficult

The Brown University Child & Adolescent Psychopharmacology Update November 1, 2019

The recent approval of esketamine (Spravato) by the Food and Drug Administration (FDA) has raised many questions for psychiatrists who treat major depression, and even bigger questions for child psychiatrists. It's not approved for pediatric use by the FDA, but that doesn't mean it can't be prescribed off‐label.

iRest Meditation for Older Adults with Depression Symptoms: 6-Month and 1-Year Follow-up

International Journal of Yoga Therapy November 1, 2019 Helané Wahbeh, Nina Fry

Abstract Preliminary positive evidence supports the use of iRest (Integrative Restoration) in older adults with depression symptoms. No long-term follow-up measures have been reported on whether the preliminary effects continue beyond initial iRest trainings. The growing population of older adults with depression symptoms is a serious public health issue, and effective interventions to support...

iRest Meditation for Older Adults with Depression Symptoms: A Pilot Study

International Journal of Yoga Therapy November 1, 2019 Helané Wahbeh, Melissa Nelson

Abstract Older adults, a rapidly growing population in the United States, have fewer physiological reserves and are more likely to be affected by stress, making them especially susceptible to depression symptoms. Meditation offers promising potential as an effective treatment; however, few studies have evaluated meditation interventions for this demographic. The objectives of this pilot study...

Internet‐delivered mindfulness‐based cognitive therapy for anxiety and depression in cancer survivors: A randomized controlled trial

Psycho-Oncology November 1, 2019 E. Nissen, M. O'Connor, Viktor Kaldo et al.

Internet‐delivered interventions may alleviate distress in cancer survivors with limited access to psychological face‐to‐face treatment. In collaboration with a group of cancer survivors, we developed and tested the efficacy of a therapist‐assisted internet‐delivered mindfulness‐based cognitive therapy (iMBCT) program for anxiety and depression in cancer survivors.

Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: A randomized controlled trial.

Psychiatry Research November 1, 2019 Jun Dong, S. Min, H. Qiu et al. 26 citations

This study aimed to investigate the efficacy and safety of intermittent low-dose ketamine on improving the efficacy of ECT. Patients diagnosed with Major Depressive Disorder (MDD) (n = 134) were randomized into 3 groups: routine ECT group (group E, n = 45); repeated ketamine-assisted ECT group (group RK, n = 43), and intermittent ketamine-assisted ECT group (group IK, n = 46). Patients in group...